Brimonidine TartrateThird Party Manufacturing in India

Brimonidine Tartrate works by selectively activating alpha-2 adrenergic receptors, which results in the reduction of aqueous humor production by the ciliary body and a simultaneous increase in uveoscleral outflow. It targets these receptors to help the body lower intraocular pressure associated with glaucoma. Unlike non-selective alpha agonists, it minimizes cardiovascular and pupillary side effects. It is highly effective and well-tolerated for intraocular pressure control.

Therapeutic Uses

• Open-Angle Glaucoma: Prescribed to lower intraocular pressure in patients diagnosed with open-angle glaucoma.
• Ocular Hypertension: Used to treat elevated ocular pressure to prevent visual field defects and optic nerve degeneration.

Why Manufacturers Choose Brimonidine Tartrate

Brimonidine Tartrate third party manufacturing in India is highly popular among ophthalmic marketers due to its established position as a first-line treatment for glaucoma. Celesta provides high-quality manufacturing oversight via specialized partner facilities that are WHO-GMP certified, ensuring full compliance with international standards and strict purity baselines. Incorporating this product enables pharmaceutical companies to secure strong relationships with ophthalmologists under reliable WHO-GMP contract manufacturing parameters.